Prevail是一家生物技术公司,致力于为神经退行性疾病患者开发潜在的基于疾病改良AAV9的基因疗法。#生物医药下一个十年# #AAV基因治疗#查看全文
消灵通2020-12-15 22:44
$Prevail Therapeutics(PRVL)$ $礼来(LLY)$ 礼来上涨2%,Prevail Therapeutics飙涨83%;礼来宣布以8.8亿美元或每股22.5美元的价格收购Prevail Therapeutics。查看全文
牛唐2020-12-15 21:55
$礼来(LLY)$ Buy $Prevail Therapeutics(PRVL)$ for $22.50/Share in Cash ,一天一个并购,$美国生科ETF-SPDR(XBI)$ 又要嗨了查看全文
华尔街操盘手_2019-06-21 00:15
$Slack Technologies(WORK)$ $Grocery Outlet(GO)$ $Prevail Therapeutics(PRVL)$ 最全ipo上市列表 网页链接查看全文
$Prevail Therapeutics(PRVL)$ 内部交易: 2021-12-30,总裁 & CEO,Abeliovich Asa ,期权,125793普通股, $9.84
$Prevail Therapeutics(PRVL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-065696 Size: 12 KB 网页链接
$Prevail Therapeutics(PRVL)$ SC 13D General statement of acquisition of beneficial ownership Accession Number: 0001193125-20-323947 Act: 34 Size: 93 KB 网页链接
$Prevail Therapeutics(PRVL)$ SC 14D9 Solicitation, recommendation statements Accession Number: 0001193125-20-323922 Act: 34 Size: 578 KB 网页链接
$Prevail Therapeutics(PRVL)$ SC TO-T Tender offer statement by Third Party Accession Number: 0001193125-20-323829 Act: 34 Size: 1 MB 网页链接
$Prevail Therapeutics(PRVL)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000899243-20-034201 Size: 10 KB 网页链接
$Prevail Therapeutics(PRVL)$ SC14D9C Written communication relating to third party tender offer Accession Number: 0001193125-20-318192 Act: 34 Size: 64 KB 网页链接
$Prevail Therapeutics(PRVL)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001193125-20-317624 Act: 34 Size: 789 KB 网页链接
$Prevail Therapeutics(PRVL)$ SC TO-C Written communication relating to an issuer or third party Accession Number: 0001193125-20-317452 Act: 34 Size: 85 KB 网页链接
$Prevail Therapeutics(PRVL)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001564590-20-053728 Act: 34 Size: 7 MB 网页链接